Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC - Episode 3

COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS

Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study demonstrated statistically significant recurrence-free intervals across various postoperative and adjuvant chemotherapy time points, highlighting the prognostic value of serial, tissue-free ctDNA assays for real-time detection of MRD vs single postchemotherapy assessments.

EP. 1: Risk of Recurrent Colorectal Cancer Following Definitive Therapy
EP. 2: COSMOS-CRC-01: Study Design and Methodology
Now Viewing
EP. 3: COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS
EP. 4: COSMOS-CRC-01: Sensitivity and Specificity of a Serial, Cell-Free DNA Epigenomic Platform in Detecting MRD in Real Time
EP. 5: Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC

1. Please summarize the statistically significant recurrence-free intervals across the postoperative, post-ACT, and paired pre- and post-ACT analyses in the COSMOS-CRC-01 study.

2. Please address the prognostic value of serial, tissue-free, epigenomic ctDNA assays in detecting MRD in real time vs a single postchemotherapy time point.

Related Content:

Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC
Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC
COSMOS-CRC-01: Sensitivity and Specificity of a Serial, Cell-Free DNA Epigenomic Platform in Detecting MRD in Real Time
COSMOS-CRC-01: Study Design and Methodology